Novo Nordisk (NVO) has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts showed.
The previously unreported cuts included staff in manufacturing roles, from quality control to production line technicians, at Novo’s major Clayton, North Carolina, plant and other facilities in the state, the report said.
The layoffs, while only a small part of a planned 9,000 job cuts globally, underscore how the Wegovy-maker is cutting back even on frontline production in the top market for the drug as it looks to sharpen its focus, trim costs, and claw back lost ground in fierce competition with rival Eli Lilly (LLY).
The North Carolina cuts hit technical manufacturing workers, project coordinators, a strategic communications manager, and an HR assistant, the posts revealed. Of the total, 47 directly posted they were looking for work or had been laid off.
